Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Current and Projected Market Size of the Tremfya Market Through 2034?

In recent times, the tremfya market has prospered, registering an HCAGR of XX. The market is projected to escalate from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. The growth experienced during the historic time period is largely due to an upsurge in cases of psoriasis and psoriatic arthritis, a sharp focus on targeted treatments, expansion in healthcare investments, an increase in specialized clinics, and the pervasive use of biologics in dermatology and rheumatology.

In the coming years, the tremfya market size projects an expected XX (FCAGR) increase. By 2029, it’s anticipated to reach a peak of $XX million, with a compound annual growth rate (CAGR) of XX%. The expansion during the prediction period is due to enhancing healthcare structure, growing utilization of point-of-care testing, elevated funding in healthcare research, and heightened interest in precision medication. The forecast period displays key trends such as progress in treatment methods, tailored medical approaches, technological convergence in patient monitoring, incorporation of artificial intelligence (AI), and advancements in injection gadgets.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp

Which Primay Drivers Are Accelerating Growth in the Tremfya Market?

The surge in the occurrence of autoimmune diseases is anticipated to drive the expansion of the tremfya market. These diseases, which are conditions where the immune system erroneously attacks the body’s cells, tissues or organs as if they were harmful intruders, have been steadily escalating. Several factors contribute to this increase, including genetic predispositions, environmental factors, lifestyle modifications, heightened awareness, and enhanced diagnostic capabilities. Tremfya, a monoclonal antibody that targets interleukin-23 (IL-23), can help control autoimmune diseases by modulating the overreactive response of the immune system, diminishing inflammation, and relieving symptoms in conditions like psoriasis and psoriatic arthritis. As an instance, a report disclosed by the Australian Institute of Health and Welfare, a governmental organization based in Australia, in June 2024 stated that there were 10,000 hospitalizations due to rheumatoid arthritis in 2022, a notable leap of 25% from the 8,000 recorded the preceding year, translating to a hospitalization rate of 39 per 100,000 people. Hence, the rising incidence of autoimmune diseases is facilitating the growth of the tremfya market.

Which Primary Segments of the Tremfya Market Are Driving Growth and Industry Transformations?

The tremfya market covered in this report is segmented –

1) By Indication: Moderate-To-Severe Plaque Psoriasis; Active PsA

2) By Formulation: Subcutaneous Injection; Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies

4) By End User: Adult Patients; Geriatric Patients

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20343&type=smp

Which Regions Are Key Players in the Growth of the Tremfya Market?

North America was the largest region in the tremfy market in 2024. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Tremfya Market?

Securing regulatory permissions to extend its therapeutic applications, such as for moderate-to-severe Crohn’s disease, is a prominent trend in the Tremfya market, which in turn enlarges its patient pool and market prospects. Regulatory permissions indicate formal approval from bodies like the Food and Drug Administration (FDA) or European Medicines Agency (EMA) sanctioning the marketing of a medicine for particular uses, provided it proves its safety, effectiveness, and quality. For instance, in September 2024, Johnson & Johnson, a pharmaceutical company from the U.S, obtained FDA endorsement for TREMFYA (guselkumab) to treat adults with moderately to severely active ulcerative colitis, making it the foremost dual-acting interleukin-23 inhibitor cleared for the condition. This ruling was grounded on the favorable findings from the Phase 2b/3 QUASAR study, showing around 50% of patients attaining clinical remission following 44 weeks of therapy. TREMFYA targets interleukin-23, assisting in standardizing the inflammatory reaction in the colon.

View the full report here:

https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report

What Parameters Are Used to Define the Tremfya Market?

Tremfya (guselkumab) is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease. It works by inhibiting interleukin-23 (IL-23), a protein involved in the inflammatory processes of these conditions. Tremfya is administered via subcutaneous injection once every 8 weeks after initial loading doses.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20343

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model